

ORIGINAL ARTICLE

Role of *Candida Albicans* Germ Tube Antibody Test in Diagnosis of Invasive Candidiasis in Intensive Care Unit at Beni-Suef University Hospital

¹Nesreen M. Kamel*, ¹Sara A. Morsy, ²Ahmed F. Azmy, ³Eiman M. AbdulRahman

¹Department of Clinical and Chemical Pathology, Faculty of Medicine, Beni -Suef University, Beni-Suef, Egypt

²Department of Microbiology Faculty of Pharmacy, Beni -Suef University, Beni-Suef, Egypt

³Department of Clinical and Chemical Pathology (Clinical Microbiology) Faculty of Medicine - Cairo University, Cairo, Egypt

ABSTRACT

Key words:

Invasive candidiasis, *Candida albicans* germ tube antibody, PCR

*Corresponding Author:

Nesreen Mostafa Kamel
Assistant professor of clinical and chemical pathology,
Faculty of Medicine, Beni-Suef University
Tel.: 01061456498
nsreen_walid@yahoo.com

Background: *Candida* species are common human commensals can cause wide range of ailments. The most serious is a spread serious infection, which happens with expanded pervasiveness in emergency unit patients. Authoritative diagnosis relies upon isolation of *Candida* from blood culture or positive cultures from other normally sterile body sites, yet this may recognize less than half of cases. Improved diagnostics are expected to control inception of antifungal treatment to diminish mortality rate. **Objective:** The aim of this study was to evaluate the potential utility of the *CALB* gene recognition PCR and the *Candida albicans* germ tube antibody test (CAGTA) as biomarkers for quickly identifying invasive candidiasis in patients who were in danger of developing the disease in emergency departments. **Methodology:** The study included 50 patients from ICU suffering from invasive *Candida* infection. For all patients, blood culture, CAGTA test and PCR for identification of *CALB* gene were done. **Results:** Taking blood culture as the gold standard for diagnosis of invasive candidiasis. The sensitivity of CAGT was 75% and the specificity was 88.1% while the sensitivity of PCR was 100% and the specificity was 83.3%. **Conclusion:** For the diagnosis of an invasive candida infection, the biomarkers PCR and CAGT have additional value.

INTRODUCTION

Common human commensals like *Candida* species can cause a variety of illnesses. A noteworthy concern is the spread of infection, which occurs more frequently in patients in intensive care units ¹.

With high rates of morbidity and mortality, invasive fungal infections (IFIs) cause a substantial disease burden. The number of patients who are at risk for IFDs is increasing, and the prevalence of drug-resistant fungal infections is also rising, which exacerbates the issue ².

Antibacterial agents are overused and widely distributed in emergency units, which disrupts the microbiota and increases candida colonization. The use of intravascular devices, elementary tract operations, and weakened body defenses promote candida invasion ³.

The development of *Candida* in blood cultures or cultures from other typically sterile sites is necessary for the definitive diagnosis, although this may not be able to differentiate more than half of the cases. Better diagnosis should guide the initiation of antifungal treatment. Therefore, it is essential to have tests that are getting faster, more accurate, and more sensitive in order to accurately and precisely identify candida infections ⁴.

Promising sensitivity and specificity allow the biomarker *Candida albicans* germ tube antibody test

and PCR assays to diagnose invasive candidiasis and candidemia prior to blood cultures ^{5, 6, 7}.

The commercially available indirect immunofluorescence test known as the *Candida albicans* germ tube-specific antibody (CAGTA) immunofluorescence assay (IFA) allows the identification of antimycelium IgG antibodies against different species of *Candida* ⁸.

Positive serum CAGTA detection is suggestive of profound situated infection in which *Candida* hyphae attack diverse body tissues. Hyphae contain hpw1 antigens which enhance generation of CAGTA ⁹.

Although that procedure was originally created for *Candida albicans*, it has been shown that other *Candida* species, such as *Candida tropicalis*, *Candida parapsilosis*, *Candida glabrata*, *Candida dubliniensis*, *Candida guilliermondii*, and *Candida krusei*, can produce CAGTA to varying degrees ¹⁰.

Many DNA-based techniques, particularly PCR, have been developed to enhance diagnosis because of its ease of use, sensitivity, and specificity. The most well-known techniques have concentrated on specific regions of the DNA found in *Candida* species. This approach has the benefit of being able to differentiate between low candidemia that occurs early in an infection ¹¹.

The aim of this study was to evaluate the potential utility of PCR of *CALB* gene and CAGTA for the quick

identification of invasive candidiasis (IC) in patients presenting to emergency departments.

METHODOLOGY

Patients:

Fifty patients who were suspected of having invasive candidiasis participated in the current study. The patients were enlisted from Beni-Suef University Hospital. Our hospital is a tertiary care hospital, affiliated to Beni-Suef University.

Data confidentiality was preserved according to the **Revised Helsinki Declaration of Bioethics**¹² Informed consent was acquired from all the patients or guardians who consented to participate in the study.

This study was approved by Research Ethical Committee, Faculty of Medicine Beni-Suef University; **Approval No: FMBSUREC/09042023/Kamel on 9th April 2023**

Every patient had a complete history taken, with particular attention paid to age, gender, underlying conditions, and factors that might predispose to an invasive fungal infection (IFI); these include immunodeficiency or neutropenia, burns, recent surgery, hemodialysis, the presence of a central venous line, diabetes mellitus, renal failure, the presence of a urinary catheter, or prolonged stays in the intensive care unit.

Patients received antifungal drugs, were excluded from the study. Patient follow up was done for three months.

The selection of patients is primarily based on the presence of one or more invasive candidiasis (IC) risk factors, such as a prolonged fever lasting longer than seven days, non-responsiveness to antibiotics¹³ candidiuria $>10^3$ CFU/ml¹⁴ with or without blood cultures that tested positive for *Candida* species.

Microbiological techniques:

a- Culture for Urine, sputum, blood and CSF:

Culture of the corresponding sample was performed on blood, chocolate, and MacConkey agar (Oxoid, England) along with blood culture using BACTEC FX 40 (Becton Dickinson, Germany) automated blood culture system, based on the suspected site of infection. *Candida* species identification was performed by colony morphology on Sabouraud dextrose agar (Oxoid, England), Gram staining and germ tube test.

b- Non-cultural techniques:

1- *Candida albicans* germ tube assay (CAGTA) Using an indirect immunofluorescence technique, the *Candida albicans* germ tube assay (CAGTA) was performed on serum samples to identify antimycelium IgG antibodies against different *Candida* species (Vircell Microbiologist S.L., Granada, Spain). The test was conducted as directed by the manufacturer.

Interpretation of results:

The highest dilution at which a positive reaction is found is known as the serum titer. When the mycelium phase exhibits apple-green fluorescence while the yeast phase remains red, the reaction is considered positive. (**Figure 1**)

The reaction was considered negative when red cell pattern over both the mycelium and yeast phases could be identifiable.




Fig. 1: show positive CAGTA (the green apple appearance)

2- Polymerase chain reaction (PCR) for *CALB* gene:

PCR procedure was done according to¹⁵ on aliquots from each patient's blood culture bottle. That procedure was done in the Microbiology Department for Research and Postgraduate Studies in Faculty of Pharmacy, Beni-Suef University.

DNA extraction:

Isolation of yeast genomic DNA from 1.5 ml of an overnight broth cultures was done according to **Harju et al.**¹⁶ Repeated freeze- defrosting of cells in a lysis buffer was used to disturb the cell wall and discharge genomic DNA. Cell lysis was trailed by extraction with chloroform and ethanol precipitation.

DNA amplification and cycling conditions:

- PCR taq master mix: red Taq PCR Master Mix (2X) (Bioline, UK).
- Primer sequence for *CALB* gene identification: the following primers were used: TTT ATC AAC TTG TCA CAC CAG A and ATC CCG CCT TAC CAC TAC CG (Invitrogen Company, UK) indicated by the method described by¹⁷.
- PCR thermal cycling conditions: DNA thermal cycler (Biometra an Analytic Jena Company, Germany and Sensquest labcycler, Germany.) were used. Thermal cycling conditions were summed up in table 1.

Table 1: Thermal cycling conditions

		CALB
Initial denaturation		94° C for 5 min
Repeated for 35 cycles	Denaturation	94° C for 5 min
	Annealing	54° C for 30s
	Extension	72° C for 30s
Final extension		72° for 5 min

Detection of PCR products:

Using a UV transilluminator and gel electrophoresis, the amplified genes were detected. (Whatman, Biometra, Germany).

The amplified gene product is expected at molecular size of 273 bp¹⁵ as shown in **Figure 2**.




Fig. 2: Gel electrophoresis of PCR amplified *CALB* gene (273 bp)
Lane M was 100 bp DNA ladder.
Lane 2,5 considered as positive for *CALB* gene .
Lane 1,3,4 considered negative for *CALB* gene

RESULTS

The age of patients ranged from 1 to 70 years with a mean value 45.6 ± 16.9 , the patients were 28 male (56%)

and 22 female (44%). The length of stay at ICU ranged from 4 to 24 days with a mean value 11.5 ± 5.0 . The clinical data of our patients is shown in table 2.

Table 2: clinical data of patients

	Total Patients (n=50)	Proven invasive candidiasis (positive blood culture) (n=8)	P value
Renal failure or on hemodialysis, renal transplant	17(34)	4(50%)	0.442
Hematological tumour or cancer on chemotherapy	8(16)	0(0%)	0.583
Neutropenia	10(20)	2(25%)	0.664
Long term broad spectrum antibiotic	38(76)	7(87.5%)	0.668
After surgery especially gastrointestinal	10(20)	2(25%)	0.664
Unexplained fever	18(36)	2(25%)	0.701
Parenteral nutrition	23(46)	6(75%)	0.252
Other sites colonization or Candiduria $cc > 10^5$	11(22)	1(12.5%)	0.987
Antifungal prophylaxis	23(46)	6(75%)	0.252

Bold values are statistically significant

Sig P < 0.05 HS P < 0.001 NS P > 0.05

It was discovered that none of the risk factors found in our patients was statistically significant for the IFI development.

Our patients were divided into two groups: those with positive blood cultures and proven IC and unproven IC in patients clinically believed to have IC but revealed negative blood culture¹⁸.

We found that 8/50 (16%) of patients had positive blood culture results (proven IC). While 11 positive candiduria cases had colony count $\geq 10^3$ CFU/ml and one of them had blood culture positive. Two sputum cases showed suppressed normal flora with overgrowth of *C. albicans*; these two cases had negative blood culture

but positive CAGTA. The number of positive CAGTA test was 11/50 (22%).

For the diagnosis of invasive candidiasis, the *Candida albicans* germ tube antibody test (CAGTA) is considered significant. (*P* value < 0.001).

Polymerase chain reaction for detection of CALB gene:

Thirteen patients (30%) in our study had positive CALB gene tests.

Considering blood culture to be the gold standard for IC diagnosis¹⁹ the sensitivity and specificity of CAGTA and PCR were calculated as shown in table 3.

Table 3: Sensitivity and Specificity of CAGTA and PCR tests:

	Sensitivity (%)	Specificity (%)	PPV	NPV	PLR	NLR
CAGT	75%	88.1%	54.5%	94.9%	6.3%	0.28%
PCR	100%	83.3%	53.3%	100%	6%	0%
Combined CAGT-PCR	56.3%	98%				

PPV=Positive Predictive Values NPV=Negative Predictive Values

PLR =likelihood NLR =negative likelihood

The overall sensitivity is greater than either alone but the specificity is less than either alone.

Patient's outcome:

Twenty-two patients (44%) died. Eight patients of them had positive blood cultures and confirmed invasive candidiasis died.

Table 4: The outcome of all patient and proven invasive candidiasis IC

	Total	Proven IC(+ve blood culture)	CAGTA +ve	PCR+ve
Death	22(44%)	8 (100%)	9	12

DISCUSSION

Although fungus infections do not usually occur as primary infections in immunocompetent individuals, they are typically associated with immunodeficiency states or the presence of underlying diseases. Invasive candidiasis infection is often more common in critically ill patients, with higher rates of morbidity and mortality²⁰. No risk factor found in our patients was found to be statistically significant for the development of IFI; Martínez-Jiménez et al.'s²¹ study revealed similar results.

Conversely, though, Martínez-Jiménez and his colleagues²² discovered that patients with candidemia had a significantly higher prevalence of traditional risk factors for *Candida* infection, such as intravenous catheterization, total parenteral nutrition, antimicrobial use, and prior *Candida* colonization. The different observation in our study might be related to our small sample size.

Because of its high specificity and relatively low sensitivity, fungal culture is the gold standard for diagnosing IC; but it can detect only about 50–71% of cases¹⁹. Not only is there restricted sensitivity, but growth and identification take a long time. One possible explanation for the negative blood culture is the lack of viable fungal cells or insufficient concentration to be detected²³.

In order to overcome the low detection level of fungal blood culture, nonculture methods were developed. Nonculture techniques have limitations, but they also have some benefits when it comes to identifying cases of IC that are misdiagnosed⁵.

Indirect immunofluorescent assay is used to find antibodies made against the *C. albicans* germ tube antigen (CAGTA). According to our research, CAGTA's sensitivity and specificity were 75% and 88.1%, respectively. Parra-Sanchez et al.²⁴ reported similar outcomes; they compared the CAGTA test with the mono-test automatic VirClia indirect chemiluminescent immunoassay; they reported sensitivity of 69.2% and specificity of 80.3%. However, Martínez-Jiménez²² mentioned lower sensitivity (58.1%) and higher specificity (92%) when used this test alone as a candidaemia biomarker. Because the test relies on the production of antibodies in patients who typically have immunodeficient states or underlying diseases, it has a wide range of specificity and sensitivity. It also can't diagnose other candida infection other than *C. albicans* as reported by Parra-Sanchez et al²⁴.

In our study, IC was reported in suspected patients using the CALB gene PCR as a tool. The test had an 83.3% specificity and 100% sensitivity. Our findings support those of Kourkoumpetis et al²⁵ who stated that the majority of studies assessing PCR-based assays for blood sample identification of *Candida* DNA report sensitivity that can reach 100% and specificity that may reach 90%.

Nevertheless, Clancy and Nguyen²⁶ reported a lower PCR specificity of 70%, which might have been influenced by a high-risk control group primarily made up of patients with *Candida* species colonization or mucosal candidiasis. Because many of the controls were immunocompromised in intensive care units, the authors discovered that some of them had undetected invasive candidiasis and had infection-related signs and symptoms but negative cultures.

The PCR assay method has demonstrated high sensitivity and specificity in certain studies; however, it has certain limitations that indicate its limited applicability in the diagnosis of IC. A small number of cells and complications during sample preparation and DNA extraction led to false negative results. Additionally, because the DNA of fungi and humans is similar, false positive results have occurred. Due to all of these factors, this test is not reliable when used alone to diagnose IC¹⁹.

CONCLUSION

Our research revealed that the polymerase chain reaction (PCR) and the *Candida albicans* germ tube antibody test (CAGTA) performed well in the diagnosis of invasive candidiasis. Because non-culture diagnostics for invasive candidiasis can identify some patients with the disease earlier than cultures, they present challenges for doctors, laboratories, and hospitals. However, these diagnostics can also improve patient outcomes, limit the emergence of resistance, reduce the need for unnecessary antifungal use, and be more affordable. The role of combination testing is also warranted. One crucial point is that for patients who are at high risk of infection, non-culture techniques should be used in addition to blood cultures, not instead of them.

Declarations:

Consent for publication: Not applicable

Availability of data and material: Data are available upon request.

Competing interests: The author(s) declare no potential conflicts of interest with respect to the research, authorship and/or publication of this article. This manuscript has not been previously published and is not under consideration in another journal.

Funding: Authors did not receive any grants from funding agencies.

Acknowledgement

I would like to express my deepest gratitude to Ph.D. Ahmed Farag Azmy; Assistant Professor of Microbiology, Faculty of Pharmacy - Beni-Suef University, Beni-Suef, Egypt; for his expertise and assistance throughout the molecular and PCR steps of our study and for his help in writing the manuscript.

REFERENCES

- Pfaller M A, Wolk D M and Lowery T J. T2MR and T2 Candida: novel technology for the rapid diagnosis of candidemia and invasive candidiasis. *Future Microbiol.* , 2015;11(1): 103–117.
- Yanru Feng a, Hui Lu a, Malcolm Whiteway b, Yuanying Jiang. Understanding fluconazole tolerance in *Candida albicans*: implications for effective treatment of candidiasis and combating invasive fungal infections. *Journal of Global Antimicrobial Resistance*, 2023; 35: 314–321
- Andrea C, Giovanni M, Teresa F, et al. Epidemiology, clinical characteristics, resistance, and treatment of infections by *Candida auris*. *Journal of Intensive Care* , 2018; 6: R 69
- Poissy J, Sendid B, Damiens S, Ishibashi K I, François N et al. Presence of *Candida* cell wall derived polysaccharides in the sera of intensive care unit patients: relation with candidaemia and *Candida* colonisation. *Crit Care* , 2014; 18(3): R135.
- León C, Ruiz-Santana S, Saavedra P, Castro C, Loza A, Zakariya I et al. Contribution of *Candida* biomarkers and DNA detection for the diagnosis of invasive candidiasis in ICU patients with severe abdominal conditions. *Crit. Care.*, 2016; 20: 149.
- Clancy C J and Nguyen M H. Non-Culture Diagnostics for Invasive Candidiasis: Promise and Unintended Consequences. *J Fungi* , 2018; 4(1): 27.
- Ensaf A A, Nahla E El-G, Wafaa S M, Marwa H A. Role of *Candida Albicans* Germ Tube Antibody in Diagnosis of Invasive Candidiasis in End Stage Liver Disease Patients. *Egypt J Immunol* , 2018; 25(1):161-170.
- Ander D, Giulia C, Marta B, María-Soledad C et al. Biomarkers for the diagnosis of invasive candidiasis in immunocompetent and immunocompromised patients. *Diagnostic Microbiology and Infectious Disease*, 2021; 101:3
- Aranzazu S, María S, and María M. Identification of superficial *Candida albicans* germ tube antigens in a rabbit model of disseminated candidiasis. A proteomic approach. *International Microbiology* , 2014; 17:21-29
- Ponton J and del Palacio A. Advances and limitations in the early diagnosis of invasive yeast infections. *Rev Iberoam Micol*, 2007; 24: 181–186 [in Spanish].
- Aida P, César N, Concha G. Diagnosis of Invasive Candidiasis: From Gold Standard Methods to Promising Leading-edge Technologies. *Curr Top Med Chem* , 2018; 18(16):1375-1392.
- Ashcroft R E. The declaration of Helsinki. *The Oxford Textbook of Clinical Research Ethics*, 2008; 141-148.
- Razzaghi R, Momen-Heravi M, Erami M and Nazeri M. Candidemia in patients with prolonged fever in Kashan, Iran. *Curr Med Mycol*, 2016; 2(3): 20-26.
- Rahbar M, Vossoghian S, Alimehr S, Abad H S E, Mohammadzadeh M, Fallah F, Tabatabaei S R, Khodadadi E and Saremi M. Prevalence of *Candida* Infection at the Intensive Care Unit with Nested Polymerase Chain Reaction (PCR) Using Primer Mixes Specific to *Candida* DNA Topoisomerase II Genes. *Arch Clin Infect Dis*, 2016;11(4):e36166.
- Luo G and Mitchell TG. Rapid identification of pathogenic fungi directly from cultures by using multiplex PCR. *J Clin Microbiol.* 2002;40:2860–2865.

16. Harju S, Fedosyuk H and Peterson K R. Rapid isolation of yeast genomic DNA: Bust n' Grab. *BMC Biotechnol*, 2004; 4:8.
17. Cleison LT, Thelma S O, Artur F D, et al. A multiplex nested PCR for the detection and identification of *Candida* species in blood samples of critically ill pediatric patients. *BMC Infect Dis*, 2014; 14: 406.
18. De Pauw B, Walsh T J, Donnelly J P, Stevens D A, Edwards J E, et al. Revised definitions of invasive fungal disease from the European organization for research and treatment of cancer/invasive fungal infections cooperative group and the national institute of allergy and infectious diseases mycoses study group (EORTC/MSG) consensus group. *Clin Infect dis*, 2008; 46(12), 1813-1821.
19. Joana A., Carles A-T. and Jordi R. How to Identify Invasive Candidemia in ICU—A Narrative Review. *Antibiotics*, 2022; 11(12), 1804
20. Vallabhaneni, S., Mody, R. K., Walker, T., and Chiller, T. The global burden of fungal diseases. *Infect. Dis. Clin. North Am.*, 2016; 30, 1–11.
21. Martínez-Jiménez M C, Muñoz P, Guinea J, Valerio M, Alonso R, Escribano P and Bouza, E. Potential role of *Candida albicans* germ tube antibody in the diagnosis of deep-seated candidemia. *Medical mycology*, 2014; 52(3), 270-275.
22. Martínez-Jiménez M C, Muñoz P, Valerio M, Alonso R, et al. *Candida* biomarkers in patients with candidaemia and bacteraemia. *Journal of Antimicrobial Chemotherapy*, 2015; 70(8), 2354-2361.
23. Pfeiffer, C.D., Samsa, G.P., Schell, W.A. et al. Quantitation of *Candida* CFU in Initial Positive Blood Cultures. *J. Clin. Microbiol*, 2011; 49, 2879–2883.
24. Parra-Sánchez, M.; The CAVA Trem Study Group; Breval, I.Z.-Y.; et al. *Candida albicans* Germ-Tube Antibody: Evaluation of a New Automatic Assay for Diagnosing Invasive Candidiasis in ICU Patients. *Mycopathologia*, 2017; 182, 645–652.
25. Kourkoumpetis T K, Fuchs B B, Coleman J J, Desalermos A and Mylonakis E. Polymerase chain reaction-based assays for the diagnosis of invasive fungal infections. *Clin Infect Dis*, 2012; 54(9), 1322-1331.
26. Clancy C J and Nguyen M H. Finding the “missing 50%” of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care. *Clin Infect Dis*, 2013; 56(9), 1284-1292.